J. Czekalla

Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

M. Lambert, D. Naber, B. Schimmelmann, 2006, The Journal of clinical psychiatry.

Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics

Thomas Kolter, J. Czekalla, T. Kolter, 2002, Psychopharmacology.

The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine.

J. Czekalla, M. Gastpar, W. Hübner, 1997, Pharmacopsychiatry.

Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

M. Lambert, D. Naber, R. Dittmann, 2007, The Journal of clinical psychiatry.

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of neuroleptic-free schizophrenic patients — a 31P-chemical shift spectroscopic-imaging study

S. Smesny, R. Rzanny, J. Czekalla, 2000, European Neuropsychopharmacology.

Why Do Physicians Switch From One Antipsychotic Agent to Another?: The "Physician Drug Stereotype"

Michael Linden, R. Dittmann, M. Linden, 2006, Journal of clinical psychopharmacology.

Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine

D. Hubl, T. Dierks, L. Frölich, 2001, Psychopharmacology.

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

J. Czekalla, C. Beasley, M. Dellva, 2001, The Journal of clinical psychiatry.